Trial Profile
Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms VICTORIA
- 08 Aug 2017 Status changed from active, no longer recruiting to completed.
- 20 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 20 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.